Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.61 |
| ▸ | ABL1 | P00519 | 5/20 | 0.61 |
| ▸ | INSR | P06213 | 5/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.61 |
| ▸ | CDK2 | P24941 | 5/20 | 0.61 |
| ▸ | PLK1 | P53350 | 4/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3009979 | 0.89 | EGFR (0.69) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL142106 | 0.87 | EGFR (0.79) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL29387336 | 0.87 | EGFR (0.79) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL2701773 | 0.86 | EGFR (0.62) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL18672222 | 0.86 | EGFR (0.58) | EGFRERBB2ABL1INSRPDGFRB | |
| Hydrochloric Acid SCHEMBL2511570 | 0.86 | EGFR (0.78) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL15000311 | 0.85 | EGFR (0.68) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL15766013 | 0.85 | EGFR (0.65) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL2702725 | 0.84 | EGFR (0.56) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL2701329 | 0.84 | EGFR (0.55) | EGFRERBB2ABL1INSRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927558-B2 | Methods for detecting and reducing impurities of Lapatinib and salts thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2015-01-06 | — | — | US | claimed |
| EP-2489661-B1 | Impurity of lapatinib and salts thereof | ITALIANA SINT SPA (IT) | 2013-11-13 | — | — | EP | claimed |
| US-20120295928-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-11-22 | — | — | US | claimed |
| EP-2489661-A1 | Impurity of lapatinib and salts thereof | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2012-08-22 | — | — | EP | claimed |
| US-9606089-B2 | Methods for detecting and reducing impurities of Lapatinib and salts thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2017-03-28 | — | — | US | disclosed |
| US-9606089-B2 | Methods for detecting and reducing impurities of Lapatinib and salts thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2017-03-28 | — | — | US | disclosed |
| US-9606089-B2 | Methods for detecting and reducing impurities of Lapatinib and salts thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2017-03-28 | — | — | US | disclosed |
| US-20150260696-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | ITALIANA SINT SPA (IT) | 2015-09-17 | — | — | US | disclosed |
| US-20150260696-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | ITALIANA SINT SPA (IT) | 2015-09-17 | — | — | US | disclosed |
| US-20150260696-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | ITALIANA SINT SPA (IT) | 2015-09-17 | — | — | US | disclosed |
| US-8927558-B2 | Methods for detecting and reducing impurities of Lapatinib and salts thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2015-01-06 | — | — | US | disclosed |
| US-8927558-B2 | Methods for detecting and reducing impurities of Lapatinib and salts thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2015-01-06 | — | — | US | disclosed |
| US-8927558-B2 | Methods for detecting and reducing impurities of Lapatinib and salts thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2015-01-06 | — | — | US | disclosed |
| EP-2489661-B1 | Impurity of lapatinib and salts thereof | ITALIANA SINT SPA (IT) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295928-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-11-22 | — | — | US | disclosed |
| US-20120295928-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-11-22 | — | — | US | disclosed |
| US-20120295928-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-11-22 | — | — | US | disclosed |
| EP-2489661-A1 | Impurity of lapatinib and salts thereof | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2012-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295928-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | SRMS, ABL1, ERBB2 | EGFR 5/4885ERBB2 3/4885ABL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.